Glaucoma News and Research

Latest Glaucoma News and Research

IBI to present data on Verisome Liquid Drug Delivery System for cystoid macular edema at ARVO 2010

Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it will present an abstract demonstrating the utility of its Verisome™ Liquid Drug Delivery System in cystoid macular edema, at the Association for Research in Vision and Ophthalmology (ARVO) 2010 annual meeting, taking place May 2-6, 2010, in Fort Lauderdale, Florida.

5 May 2010

Schepens Eye Research Institute scientist selected for Otto Schade Prize

Dr. Eli Peli, a senior scientist at Schepens Eye Research Institute, has been selected by the Society for Information Display for the Otto Schade Prize. Peli will receive the award at a special presentation at the Society's Awards Banquet on May 24, 2010 in Seattle.

4 May 2010

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.

From Santen Pharmaceutical Co., Ltd. 3 May 2010

Latinos have higher rates of developing visual impairment than non-Hispanic whites: Researchers

Latinos have higher rates of developing visual impairment, blindness, diabetic eye disease, and cataracts than non-Hispanic whites, researchers found. These are the first estimates of visual impairment and eye disease development in Latinos, the largest and fastest growing minority population in the United States.

3 May 2010

IRIDEX commences commercial shipment of IQ 532 laser systems

IRIDEX Corporation, today announced the commencement of commercial shipment of the IQ 532 laser systems. The IQ 532 is a high-power, 532 nm, dual port multi-purpose laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma; and for use by otolaryngologists to correct certain types of conductive hearing loss.

30 Apr 2010

ISTA Pharmaceuticals first-quarter net revenues up 39%

ISTA Pharmaceuticals, Inc., today reported financial results for the quarter ended March 31, 2010. First quarter 2010 net revenues were $28.3 million, an increase of 39% from the first quarter of 2009. Net income for the first quarter ended March 31, 2010, was $0.5 million, or $0.01 per share, compared to a net loss of $19.6 million, or $0.59 per share, for the first quarter ended March 31, 2009.

30 Apr 2010

pSivida announces presentations on bioerodible technologies for degenerative eye disease

pSivida Corp., a leader in the development of back of the eye drug delivery systems, today announced that two poster presentations will be made at the upcoming ARVO meeting on one of pSivida's next generation bioerodible technologies for degenerative eye disease. It marks a key step toward the ability to use pSivida's bioerodible technologies to develop treatments for glaucoma and other degenerative eye diseases, diseases that affect millions of Americans.

30 Apr 2010

DRCR Network study finds new treatment more effective

28 Apr 2010

Better vision ahead for many diabetic retinopathy patients

A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration (AMD). Treating diabetic macular edema (DME) with ranibizumab (Lucentis) eye injections, plus laser treatment if needed, appears to result in better vision than laser treatment alone, according to the Diabetic Retinopathy Clinical Research (DRCR) Network study published today in Ophthalmology online, the journal of the American Academy of Ophthalmology (Academy). DME is the main cause of vision loss in people with diabetes mellitus.

27 Apr 2010

Court of Appeals denies McNeil Pediatrics' CONCERTA patent appeal

The Court of Appeals for the Federal Circuit has denied an appeal by McNeil Pediatrics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., to overturn a 2009 decision by the U.S. District Court of Delaware that the patent for CONCERTA (methylphenidate HCl) Extended-Release Tablets CII is invalid and not infringed by Andrx Corporation.

27 Apr 2010

DeCODE scientists discover common SNPs that increase number of CPD and risk of lung cancer

Cigarette smoking is a major cause of illness and death worldwide. But it is a complex behavior, and how much people smoke, how hard they find it to quit, and the impact of long-term smoking on health varies greatly among individuals. A substantial portion of this variability is genetic. Two years ago, deCODE discovered the first common, single-letter variation in the sequence of the human genome, on chromosome 15q25, associated with nicotine addiction and risk of lung cancer.

26 Apr 2010

Colorado Governor moves forward with implementing reforms; Nevada community health centers feel financial pinch

In Colorado, "Gov. Bill Ritter signed four bills he promised will rein in skyrocketing health care costs on Tuesday and appointed a director who will oversee 10 state agencies to implement the Obama administration's new health care plan.

22 Apr 2010

Medical use of marijuana on its way to reality in Washington D.C.

After debate the Washington, D.C., city council has voted unanimously for use of marijuana for medical purposes in patients with “chronic and lasting disease” like HIV, glaucoma, cancer, severe pain, multiple sclerosis etc.

22 Apr 2010

Green tea catechins may protect against glaucoma and other common eye diseases: Scientists

Scientists have confirmed that the healthful substances found in green tea - renowned for their powerful antioxidant and disease-fighting properties - do penetrate into tissues of the eye. Their new report, the first documenting how the lens, retina, and other eye tissues absorb these substances, raises the possibility that green tea may protect against glaucoma and other common eye diseases.

22 Apr 2010

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.

15 Apr 2010

STAAR Surgical reports 12% increase in first-quarter 2010 revenue

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported that revenue for the first quarter ended April 3, 2010 grew approximately 12% as compared to the first quarter of 2009.

13 Apr 2010

Tβ4 therapy for ocular disorders closer to reality

RegeneRx Biopharmaceuticals, Inc. announced today that Tβ4, a synthetic version of a naturally occurring peptide that is the basis for the company's product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010.

9 Apr 2010

Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing

Altheos, Inc., a privately held early-stage biopharmaceutical company, announced today that it has completed a $20 million Series A financing led by Bay City Capital. New investors Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital also joined the round. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor Altheos licensed from Japanese pharmaceutical company Asahi Kasei Pharma. The license also includes a series of highly active compounds (AK138 series) specifically for topical treatment for glaucoma.

5 Apr 2010

STAAR Surgical Company enters into 'Stipulation for Settlement' to resolve pending disputes

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that STAAR and all other parties to the matters Parallax Medical Systems v. STAAR Surgical Company and Scott C. Moody, Inc. v. STAAR Surgical Company entered into a Stipulation for Settlement that globally resolves all pending disputes among them.

31 Mar 2010

Optometrists and dietitians are important part of health care team

For people with diabetes, proper nutrition can have a far-reaching effect on their health and wellness. They also have a higher risk of developing vision problems. March is National Nutrition Month and Save Your Vision Month, and the American Dietetic Association (ADA) and American Optometric Association (AOA) would like to remind people that optometrists and registered dietitians are an important part of the health care team.

31 Mar 2010

Glaucoma News and Research

Latest Glaucoma News and Research

IBI to present data on Verisome Liquid Drug Delivery System for cystoid macular edema at ARVO 2010

Schepens Eye Research Institute scientist selected for Otto Schade Prize

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

Latinos have higher rates of developing visual impairment than non-Hispanic whites: Researchers

IRIDEX commences commercial shipment of IQ 532 laser systems

ISTA Pharmaceuticals first-quarter net revenues up 39%

pSivida announces presentations on bioerodible technologies for degenerative eye disease

DRCR Network study finds new treatment more effective

Better vision ahead for many diabetic retinopathy patients

Court of Appeals denies McNeil Pediatrics' CONCERTA patent appeal

DeCODE scientists discover common SNPs that increase number of CPD and risk of lung cancer

Colorado Governor moves forward with implementing reforms; Nevada community health centers feel financial pinch

Medical use of marijuana on its way to reality in Washington D.C.

Green tea catechins may protect against glaucoma and other common eye diseases: Scientists

Combivent Inhalation Aerosol's "essential use" status effective through 2013

STAAR Surgical reports 12% increase in first-quarter 2010 revenue

Tβ4 therapy for ocular disorders closer to reality

Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing

STAAR Surgical Company enters into 'Stipulation for Settlement' to resolve pending disputes

Optometrists and dietitians are important part of health care team

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Glaucoma News and Research

Latest Glaucoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in